Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

GSK Investigational Site, Follebu

GSK Investigational Site, San Miguel de Tucumán

GSK Investigational Site, Stavanger

GSK Investigational Site, Mendoza

GSK Investigational Site, Trondheim

GSK Investigational Site, Mar del Plata

GSK Investigational Site, Levanger

GSK Investigational Site, Harstad

GSK Investigational Site, Berlin

GSK Investigational Site, Tallinn

GSK Investigational Site, Berlin

GSK Investigational Site, Tallinn

GSK Investigational Site, Potsdam

GSK Investigational Site, Hamburg

GSK Investigational Site, Großhansdorf

GSK Investigational Site, Richmond

GSK Investigational Site, Spartanburg

GSK Investigational Site, Greenville

GSK Investigational Site, Birmingham

GSK Investigational Site, Tartu

GSK Investigational Site, Mainz

GSK Investigational Site, Rochester

GSK Investigational Site, Frankfurt am Main

GSK Investigational Site, Frankfurt am Main

GSK Investigational Site, Saint Charles

GSK Investigational Site, Gelnhausen

GSK Investigational Site, Rüsselsheim am Main

GSK Investigational Site, Ostrava - Poruba

GSK Investigational Site, Donetsk

GSK Investigational Site, Donetsk

GSK Investigational Site, Torrance

GSK Investigational Site, Charleston

GSK Investigational Site, Rosario

GSK Investigational Site, Buenos Aires

GSK Investigational Site, Buenos Aires

GSK Investigational Site, Mendoza

GSK Investigational Site, Prague

GSK Investigational Site, Tábor

GSK Investigational Site, Zlín

GSK Investigational Site, Bergen

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Kiev

GSK Investigational Site, Kyiv

GSK Investigational Site, Kyiv